- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04340518
Conjunctival Rebound After Scleral Lens Wear
January 28, 2021 updated by: MKWalker, University of Houston
Measuring the Recovery of the Conjunctival Tissue After 4 Days of Scleral Lens Wear
Scleral lenses, customized rigid contact lenses that land on the soft and spongy conjunctival tissue overlying the sclera, will be fitted on 15 subjects with normal ocular surfaces.
The purpose of the study is to determine the amount of conjunctival compression caused by the devices and the length of time required for the shape to recover from compression.
Study Overview
Detailed Description
The purpose of this study is to determine the interval required for the conjunctival tissue to return to its natural shape after scleral lens wear.
All study visits will take place at the University of Houston College of Optometry (UHCO).
Subjects will be recruited and fitted with scleral lenses to wear during the experimental days.
Once the proper fit has been achieved, subjects will wear the scleral lens for 4 days total, returning after the 1st and 4th day of lens wear for approximately 2 hours of testing.
The subjects will then return every 24-hours for measurements until their conjunctival shape has returned to the original shape.
The testing will be done using the sMap scleral topographer, which measures the elevation of the conjunctiva.
Testing is non-invasive although it requires instillation of Fluress eye drops, a sodium fluorescein dye with anesthetic that allows for imaging.
The total number of visits is 9-14 and the length of visit ranges from 10 minutes to 2.5 hours.
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77204
- University of Houston College of Optometry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Normal ocular surface without conjunctival or scleral disease
- Male or female
- 18 years of age and older prior to the initial visit
- A non-scleral lens wearer.
Exclusion Criteria:
- Individuals with anterior segment ocular pathology that may affect intraocular pressure and/or scleral/conjunctival health.
- Individuals with known adverse response to Fluress® ophthalmic drops
- Individuals with a history of habitual scleral lens wear
- If a usable baseline image is unable to be obtained at the initial visit due to small ocular surface area or eyelid anatomy
- Individuals currently taking any ocular medications that could affect intraocular pressure and/or scleral/conjunctival health
- Individuals who have any other conditions or situations which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Post-scleral lens wear
Normal subjects without ocular diseased who have worn scleral lenses for at least 8 hours.
|
Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rebound at 120 minutes post-SL removal, Day 4
Time Frame: Measured 120-130 minutes post-SL removal, Day 4
|
Conjunctival rebound amount at 120 minutes post-removal, Day 4
|
Measured 120-130 minutes post-SL removal, Day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rebound at 120-hours post-SL discontinuation
Time Frame: Measured 115-125 hours post-SL removal
|
Conjunctival rebound amount at 120 hours post-removal
|
Measured 115-125 hours post-SL removal
|
Rebound at 168-hours post-SL discontinuation
Time Frame: Measured 160-170 hours post-SL removal
|
Conjunctival rebound amount at 168 hours post-removal
|
Measured 160-170 hours post-SL removal
|
Rebound at 144-hours post-SL discontinuation
Time Frame: Measured 140-150 hours post-SL removal
|
Conjunctival rebound amount at 144 hours post-removal
|
Measured 140-150 hours post-SL removal
|
Rebound at 72-hours post-SL discontinuation
Time Frame: Measured 60-80 hours post-SL removal
|
Conjunctival rebound amount at 72 hours post-removal
|
Measured 60-80 hours post-SL removal
|
Rebound at 90 minutes post-SL removal, Day 4
Time Frame: Measured 90-100 minutes post-SL removal, Day 4
|
Conjunctival rebound amount at 90 minutes post-removal, Day 4
|
Measured 90-100 minutes post-SL removal, Day 4
|
Rebound at 90 minutes post-SL removal, Day 1
Time Frame: Measured 90-100 minutes post-SL removal, Day 1
|
Conjunctival rebound amount at 90 minutes post-removal, Day 1
|
Measured 90-100 minutes post-SL removal, Day 1
|
Rebound at 60 minutes post-SL removal, Day 4
Time Frame: Measured 60-70 minutes post-SL removal, Day 4
|
Conjunctival rebound amount at 60 minutes post-removal, Day 4
|
Measured 60-70 minutes post-SL removal, Day 4
|
Rebound at 30 minutes post-SL removal, Day 1
Time Frame: Measured 30-40 minutes post-SL removal, Day 1
|
Conjunctival rebound amount at 30 minutes post-removal, Day 1
|
Measured 30-40 minutes post-SL removal, Day 1
|
Rebound at 24-hours post-SL discontinuation
Time Frame: Measured 20-30 hours post-SL removal
|
Conjunctival rebound amount at 24 hours post-removal
|
Measured 20-30 hours post-SL removal
|
Rebound at 5 minutes post-SL removal, Day 1
Time Frame: Measured 5-10 minutes post-SL removal, Day 1
|
Conjunctival rebound amount at 5 minutes post-removal, Day 1
|
Measured 5-10 minutes post-SL removal, Day 1
|
Rebound at 30 minutes post-SL removal, Day 4
Time Frame: Measured 30-40 minutes post-SL removal, Day 4
|
Conjunctival rebound amount at 30 minutes post-removal, Day 4
|
Measured 30-40 minutes post-SL removal, Day 4
|
Rebound at 120 minutes post-SL removal, Day 1
Time Frame: Measured 120-130 minutes post-SL removal, Day 1
|
Conjunctival rebound amount at 120 minutes post-removal, Day 1
|
Measured 120-130 minutes post-SL removal, Day 1
|
Rebound at 5 minutes post-SL removal, Day 4
Time Frame: Measured 5-10 minutes post-SL removal, Day 4
|
Conjunctival rebound amount at 5 minutes post-removal, Day 4
|
Measured 5-10 minutes post-SL removal, Day 4
|
Rebound at 60 minutes post-SL removal, Day 1
Time Frame: Measured 60-70 minutes post-SL removal, Day 1
|
Conjunctival rebound amount at 60 minutes post-removal, Day 1
|
Measured 60-70 minutes post-SL removal, Day 1
|
Rebound at 48-hours post-SL discontinuation
Time Frame: Measured 40-50 hours post-SL removal
|
Conjunctival rebound amount at 48 hours post-removal
|
Measured 40-50 hours post-SL removal
|
Rebound at 96-hours post-SL discontinuation
Time Frame: Measured 90-100 hours post-SL removal
|
Conjunctival rebound amount at 96 hours post-removal
|
Measured 90-100 hours post-SL removal
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2019
Primary Completion (Actual)
May 1, 2020
Study Completion (Actual)
May 30, 2020
Study Registration Dates
First Submitted
February 3, 2020
First Submitted That Met QC Criteria
April 8, 2020
First Posted (Actual)
April 9, 2020
Study Record Updates
Last Update Posted (Actual)
January 29, 2021
Last Update Submitted That Met QC Criteria
January 28, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00001908
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Conjunctival Diseases
-
Dr. Guy Ben-Simon, MDCompleted
-
The New York Eye Cancer CenterGenentech, Inc.Completed
-
Sun Yat-sen UniversityRecruitingConjunctival Neoplasms | Eye Neoplasms | Orbital NeoplasmsChina
-
Alcon ResearchCompletedConjunctival StainingUnited States
-
Alcon ResearchCompletedConjunctival StainingUnited States
-
Ahmad TarhiniNational Cancer Institute (NCI)CompletedIntraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)United States
-
Johnson & Johnson Vision Care, Inc.CompletedLid-Parallel Conjunctival FoldsGermany
-
Balikesir UniversityNot yet recruiting
-
Vrije Universiteit BrusselRecruiting
Clinical Trials on Scleral lens
-
Coopervision, Inc.Not yet recruiting
-
University of HoustonCompletedOcular HypertensionUnited States
-
Mayo ClinicRecruitingOcular HypertensionUnited States
-
Jennifer FogtCompleted
-
Seoul National University HospitalCompletedOcular Surface Disease
-
University of RochesterBoston Sight; Ovitz CorporationCompletedKeratoconusUnited States
-
University of California, Los AngelesNational Eye Institute (NEI); California Institute for Regenerative Medicine...Recruiting
-
University of WaterlooPrecision Technology Services LtdCompleted
-
St. Erik Eye HospitalUmeå UniversityCompleted
-
Shanghai Eye Disease Prevention and Treatment CenterShanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shandong University of Traditional Chinese MedicineNot yet recruiting